Startups
GeoVax (Nasdaq: GOVX ) is a biotechnology company specializing in the creation, development, and com
Overview
Location
United States, Georgia, Smyrna
Employees
11-50
Phone
+1 678-384-7220
Total raised
$10M
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 21
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 29, 2024 | 3 Penny Stocks Ready to Break Out in 2025 Vuzix, GeoVox Labs, and Cardiol Therapeutics emerged as notable penny stocks late in 2024 for their potential to scale operations and launch new products. | Known for their uncommonly pronounced risk/reward profile, penny stocks all too often entice investors with their low prices and potential for significant returns, only to fail to live up to those expectations. The world of penny stocks is... |
| Nov 26, 2024 | GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference | ATLANTA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will present... |
| Nov 19, 2024 | GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia | GEO-CM04S1 Improved Immune Response vs mRNA Vaccine ATLANTA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today ... |
| Nov 12, 2024 | GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update | Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024 Gedeptin® on track to advance into Phase 2 clinical trial for first recurren... |
| Nov 5, 2024 | GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024 | GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announc... |
| Oct 2, 2024 | ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City | Conference to Feature Leading Healthcare Companies and Institutional Investors for 1x1/Small Group Meetings and Panels NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to a... |
| Oct 2, 2024 | GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference | ATLANTA, Ga., Oct. 02, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will pa... |
| Oct 2, 2024 | GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference | ATLANTA, Ga., Oct. 02, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will pa... |
| Jul 31, 2024 | GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review | Company plans Phase 2 trial in first-recurrence head & neck cancer, in combination with immune checkpoint inhibitor ATLANTA, GA, July 31, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company ... |
Show more
Reviews 0
FAQ about GeoVax Labs, Inc.
How much funding has GeoVax Labs, Inc. raised?
GeoVax Labs, Inc. has raised $10M in total across 1 funding round.
What has the press written about GeoVax Labs, Inc.?
Parsers VC has collected 21 articles mentioning GeoVax Labs, Inc., among them “3 Penny Stocks Ready to Break Out in 2025 Vuzix, GeoVox Labs, and Cardiol Therapeutics emerged as notable penny stocks late in 2024 for their potential to sc...” (Nov 29, 2024) and “GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference” (Nov 26, 2024).
Is GeoVax Labs, Inc. still active?
GeoVax Labs, Inc. is probably closed: its latest activity on Parsers VC dates from Aug 25, 2025.